Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Completed 6Terminated 5Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Small Cell 1Brain Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × RRx-001 × Clear all
NCT04525014 2024-10-31

PIRATE

EpicentRx, Inc.

Phase 1 Terminated
2 enrolled
CNS

Brain Neoplasms, Neoplasms, Spinal Cord Neoplasms, Central Nervous System Neoplasms

NCT02452970 2024-04-24

EPIC

EpicentRx, Inc.

Phase 2 Terminated
4 enrolled 6 charts
Gastrointestinal

Cholangiocarcinoma

NCT03699956 2024-03-26

REPLATINUM

EpicentRx, Inc.

Phase 3 Terminated
18 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT02801097 2022-05-17

PAYLOAD

EpicentRx, Inc.

Phase 1 Terminated
28 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02096341 2016-01-21

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

EpicentRx, Inc.

Phase 1 Terminated
2 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡